0000899243-18-004480.txt : 20180220 0000899243-18-004480.hdr.sgml : 20180220 20180220060730 ACCESSION NUMBER: 0000899243-18-004480 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180102 FILED AS OF DATE: 20180220 DATE AS OF CHANGE: 20180220 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lowrance David L CENTRAL INDEX KEY: 0001408498 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32157 FILM NUMBER: 18622884 MAIL ADDRESS: STREET 1: 422 WILLIAM WALLACE DRIVE CITY: FRANKLIN STATE: TN ZIP: 37064 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Savara Inc CENTRAL INDEX KEY: 0001160308 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841318182 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 900 S. CAPITAL OF TEXAS HIGHWAY STREET 2: SUITE 150 CITY: AUSTIN STATE: TX ZIP: 78746 BUSINESS PHONE: 512-614-1848 MAIL ADDRESS: STREET 1: 900 S. CAPITAL OF TEXAS HIGHWAY STREET 2: SUITE 150 CITY: AUSTIN STATE: TX ZIP: 78746 FORMER COMPANY: FORMER CONFORMED NAME: Mast Therapeutics, Inc. DATE OF NAME CHANGE: 20130312 FORMER COMPANY: FORMER CONFORMED NAME: ADVENTRX PHARMACEUTICALS INC DATE OF NAME CHANGE: 20030613 FORMER COMPANY: FORMER CONFORMED NAME: BIOKEYS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20010928 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-01-02 0 0001160308 Savara Inc SVRA 0001408498 Lowrance David L 900 S. CAPITAL OF TEXAS HIGHWAY, SUITE 150 AUSTIN TX 78746 0 1 0 0 Chief Financial Officer Common Stock 2018-01-02 4 M 0 31894 1.51 A 33994 D Common Stock 2018-01-02 4 F 0 3239 15.06 D 30755 D Common Stock 2018-02-15 4 S 0 4936 12.6999 D 25819 D Common Stock 2018-02-15 4 S 0 2064 13.2959 D 23755 D Employee Stock Option (right to buy) 1.51 2018-01-02 4 M 0 31894 0.00 D 2026-10-25 Common Stock 31894 95684 D The sales reported on this Form 4 for February 15, 2018 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2017. The price reported is a weighted average sale price. The sale prices ranged from $12.31 to $12.96. The price reported is a weighted average sale price. The sale prices ranged from $13.00 to $13.71. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. The shares subject to the option vest and become exercisable in sixteen equal quarterly installments beginning on February 1, 2017. /s/ David L. Lowrance 2018-02-16